Pfizer/ BioNTech’s jointly developed COVID-19 vaccine emerges extremely effective against the virus in a study that was conducted among 1.2 million Israeli people, Bloomberg reports, citing a study conducted by the teams from the Clalit Research Institute and Harvard University.
Additional details
“Two doses of the vaccine prevented 94% of Covid-19 cases in 596,618 people vaccinated between Dec. 20 and Feb. 1, about one-quarter of whom were over the age of 60.”
“After two doses, the vaccine was just as effective for adults age 70 and older as it was for younger people. There were indications that the shot might work slightly less well for people who were sick with three or more other illnesses, such as high blood pressure and diabetes.”
“But the benefit remained strong, with 89% protection from Covid symptoms seven days after the second dose. And for most people, protection was already significant two to three weeks after the first dose.”
Market reaction
The encouraging vaccine news could likely add to the reflation trade-optimism, as the S&P 500 futures rise 0.19% to 3,930 levels.
作者：Dhwani Mehta，文章来源FXStreet，版权归原作者所有，如有侵权请联系本人删除。
风险提示：本文所述仅代表作者个人观点，不代表 Followme 的官方立场。Followme 不对内容的准确性、完整性或可靠性作出任何保证，对于基于该内容所采取的任何行为，不承担任何责任，除非另有书面明确说明。
加载失败()